Affective morbidity after cancer diagnosis: Nationwide incidence and pharmacotherapy patterns across five major cancer types
Journal of Affective Disorders · 2026
DOI: 10.1016/j.jad.2026.121307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Daun Shin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, K…. Hauptthemen laut MEDLINE: Anxiety Disorders, Neoplasms, Adjustment Disorders, Depressive Disorder. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Psychiatric morbidity after cancer diagnosis impairs quality of life and may worsen survival. Cancer-type-specific risks and real-world pharmacotherapy patterns in Asian populations remain incompletely defined. We estimated the post-diagnosis incidence of depression, anxiety disorder, and adjustment disorder in five common cancers and characterized psychotropic treatment using dose-standardized exposure. METHODS: Nationwide Korean claims from the Health Insurance Review and Assessment Service were used to assemble incident cohorts of thyroid, colorectal, lung, breast, and gastric cancers. Psychiatric outcomes after diagnosis were identified, and hazard ratios were estimated with multivariable Cox models adjusting for age, sex, socioeconomic status, and comorbidity. Among patients with any diagnosis, psychotropic utilization and dose-standardized exposure were summarized using WHO-defined daily dose metrics. RESULTS: The cohort included 550,829 patients. The post-diagnosis incidence was 12.1% for depression (range by cancer 9.4-14.6%), 13.3% for anxiety disorder (11.5-15.8%), and 1.7% for adjustment disorder (1.2-2.9%), with the highest burden for breast and lung cancer and the lowest for thyroid cancer. Female, older age, lower economic status, and higher comorbidity were associated with increased risk for psychiatric disorders across cancer types. Among those diagnosed, antidepressant use was 43% and benzodiazepine use was 70%, with higher dose-standardized benzodiazepine exposure. CONCLUSIONS: Affective disorders after cancer diagnosis were common but cancer-type specific, with higher risk in vulnerable subgroups. Pharmacotherapy was marked by high benzodiazepine use and comparatively lower antidepressant treatment and exposure. These findings support cancer type and risk stratified screening, linkage to mental health care, and guideline concordant treatment, including benzodiazepine stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea.
- Department of Psychiatry, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea. Electro…
- Department of Health Administration, College of Nursing and Health, Kongju National University, Gongju, Republic of Korea. Electronic address: khkim112@kongju.ac.kr.
Zitieren
APA
Shin, D., Ham, B. J., & Kim, K. H. (2026). Affective morbidity after cancer diagnosis: Nationwide incidence and pharmacotherapy patterns across five major cancer types. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2026.121307
Vancouver
Shin D, Ham BJ, Kim KH. Affective morbidity after cancer diagnosis: Nationwide incidence and pharmacotherapy patterns across five major cancer types. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2026.121307
BibTeX
@article{Shin2026,
author = {Shin, Daun and Ham, Byung-Joo and Kim, Kyoung-Hoon},
title = {Affective morbidity after cancer diagnosis: Nationwide incidence and pharmacotherapy patterns across five major cancer types},
journal = {Journal of Affective Disorders},
year = {2026},
doi = {10.1016/j.jad.2026.121307}
}
EUVIMED